Paul C. Canniff

614 total citations
19 papers, 518 citations indexed

About

Paul C. Canniff is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Paul C. Canniff has authored 19 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 8 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Paul C. Canniff's work include Cardiac electrophysiology and arrhythmias (6 papers), Ion channel regulation and function (5 papers) and Cardiac pacing and defibrillation studies (4 papers). Paul C. Canniff is often cited by papers focused on Cardiac electrophysiology and arrhythmias (6 papers), Ion channel regulation and function (5 papers) and Cardiac pacing and defibrillation studies (4 papers). Paul C. Canniff collaborates with scholars based in United States, Brazil and Germany. Paul C. Canniff's co-authors include Douglas C. Hanson, Steven H. Bernstein, Ross Bentley, Paul J. Silver, A. Farah, Robert Millham, Jesús Gómez-Navarro, Deborah J. Guyot, Amarnath Sharma and Antoni Ribas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Pharmacology.

In The Last Decade

Paul C. Canniff

19 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul C. Canniff United States 11 243 185 150 147 67 19 518
Petra Quass Germany 12 358 1.5× 182 1.0× 26 0.2× 59 0.4× 55 0.8× 18 575
Audrey Varin France 12 294 1.2× 155 0.8× 50 0.3× 60 0.4× 34 0.5× 18 430
Rieko Takanabe‐Mori Japan 8 251 1.0× 141 0.8× 71 0.5× 68 0.5× 15 0.2× 8 502
A. Wieczorek Germany 12 199 0.8× 93 0.5× 28 0.2× 35 0.2× 28 0.4× 22 395
Kyle T. Keyes United States 7 206 0.8× 102 0.6× 51 0.3× 47 0.3× 38 0.6× 7 492
Ekaterina Kintsurashvili United States 13 162 0.7× 187 1.0× 29 0.2× 75 0.5× 43 0.6× 17 496
Benedikt Fels Germany 12 191 0.8× 61 0.3× 44 0.3× 63 0.4× 17 0.3× 26 481
Lan Wu Japan 7 224 0.9× 281 1.5× 26 0.2× 58 0.4× 30 0.4× 10 465
Katalin Hantó Hungary 9 216 0.9× 88 0.5× 184 1.2× 30 0.2× 14 0.2× 10 404
Dimitar P. Zankov Japan 16 465 1.9× 455 2.5× 56 0.4× 18 0.1× 109 1.6× 30 657

Countries citing papers authored by Paul C. Canniff

Since Specialization
Citations

This map shows the geographic impact of Paul C. Canniff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul C. Canniff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul C. Canniff more than expected).

Fields of papers citing papers by Paul C. Canniff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul C. Canniff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul C. Canniff. The network helps show where Paul C. Canniff may publish in the future.

Co-authorship network of co-authors of Paul C. Canniff

This figure shows the co-authorship network connecting the top 25 collaborators of Paul C. Canniff. A scholar is included among the top collaborators of Paul C. Canniff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul C. Canniff. Paul C. Canniff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ribas, Antoni, Douglas C. Hanson, Dennis A. Noe, et al.. (2007). Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. The Oncologist. 12(7). 873–883. 136 indexed citations
2.
Millham, Robert, Dmitri Pavlov, Paul C. Canniff, et al.. (2006). Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206). Journal of Clinical Oncology. 24(18_suppl). 2542–2542. 3 indexed citations
3.
Hanson, Douglas C., Paul C. Canniff, Michael J. Primiano, et al.. (2004). Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.. Cancer Research. 64. 877–877. 30 indexed citations
4.
Canniff, Paul C., et al.. (2004). CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease. 64. 164–164. 11 indexed citations
5.
Hanson, Douglas C., Angela Nguyen, Robert J. Mather, et al.. (1999). UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation. British Journal of Pharmacology. 126(8). 1707–1716. 62 indexed citations
6.
Nguyen, Angela, John C. Kath, Douglas C. Hanson, et al.. (1996). Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.. Molecular Pharmacology. 50(6). 1672–1679. 93 indexed citations
7.
8.
Horan, Patrick, et al.. (1992). Myocardial salvage by trolox and ascorbic acid, but not ascorbic acid alone, in anesthetized dogs and rabbits. Drug Development Research. 27(4). 345–360. 4 indexed citations
9.
Canniff, Paul C., et al.. (1991). Comparative hemodynamic and renal effects of the low Km cGMP phosphodiesterase inhibitors cicletanine and zaprinast in anesthetized dogs. Drug Development Research. 23(2). 127–144. 6 indexed citations
10.
Canniff, Paul C., et al.. (1991). Cardiovascular and renal effects of milrinone in beta-adrenoreceptor blocked and non-blocked anaesthetized dogs.. PubMed. 17(3). 145–58. 6 indexed citations
11.
Ezrin, Alan M., et al.. (1990). Cardiovascular effects of medorinone in β‐adrenoreceptor‐blocked and non‐blocked anesthetized dogs. Drug Development Research. 21(2). 119–133. 3 indexed citations
12.
Silver, Paul J., et al.. (1990). Activation of the cAMP system by medorinone correlates with positive inotropy or vasorelaxation. Drug Development Research. 21(2). 105–117. 2 indexed citations
13.
Silver, Paul J., Alex L. Harris, Paul C. Canniff, et al.. (1989). Phosphodiesterase Isozyme Inhibition, Activation of the cAMP System, and Positive Inotropy Mediated by Milrinone in Isolated Guinea Pig Cardiac Muscle. Journal of Cardiovascular Pharmacology. 13(4). 530–540. 48 indexed citations
14.
Silver, Paul J., Alex L. Harris, Paul C. Canniff, et al.. (1989). Phosphodiesterase Isozyme Inhibition, Activation of the cAMP System, and Positive Inotropy Mediated by Milrinone in Isolated Guinea Pig Cardiac Muscle. Journal of Cardiovascular Pharmacology. 13(4). 530–540. 51 indexed citations
15.
Farah, A., Paul C. Canniff, Ross Bentley, & Crist Frangakis. (1988). The Effect of Extracellular Ca2+ and Related Ions on the Cardiac Action of Milrinone. Journal of Cardiovascular Pharmacology. 11(5). 591–600. 13 indexed citations
16.
Farah, A., et al.. (1987). Effect of Milrinone (Corotrope) on the Contractility of Isolated Dog Ventricular Muscle. Journal of Cardiovascular Pharmacology. 10(6). 607–615. 18 indexed citations
17.
Canniff, Paul C., A. Farah, N. Sperelakis, & Gordon M. Wahler. (1985). The Effect of Milrinone (Win 47203) on the In Vitro Electropharmacological Properties of Mammalian Cardiac Tissue. Journal of Cardiovascular Pharmacology. 7(5). 813–821. 10 indexed citations
18.
Healey, John F., et al.. (1983). Electrophysiological Actions of Amrinone in Dogs with Cardiac Lesions. Journal of Cardiovascular Pharmacology. 5(6). 1052–1052. 13 indexed citations
19.
Canniff, Paul C., et al.. (1983). In Vitro Electrophysiologic Properties of Amrinone in Mammalian Cardiac Tissue. Journal of Cardiovascular Pharmacology. 5(6). 1040–1067. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Petra Quass Breakdown of academic impact, for papers by Audrey Varin Breakdown of academic impact, for papers by Rieko Takanabe‐Mori Breakdown of academic impact, for papers by A. Wieczorek Breakdown of academic impact, for papers by Kyle T. Keyes Breakdown of academic impact, for papers by Ekaterina Kintsurashvili Breakdown of academic impact, for papers by Benedikt Fels Breakdown of academic impact, for papers by Lan Wu Breakdown of academic impact, for papers by Katalin Hantó Breakdown of academic impact, for papers by Dimitar P. Zankov
Rankless by CCL
2026